Critical Comparison: DBV Technologies (DBVT) and Quidel Corporation (QDEL)

Quidel Corporation (NASDAQ: QDEL) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitabiliy, analyst recommendations, risk, dividends and earnings.

Analyst Ratings

This is a summary of current ratings for Quidel Corporation and DBV Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quidel Corporation 0 3 1 0 2.25
DBV Technologies 0 0 6 0 3.00

Quidel Corporation presently has a consensus price target of $24.67, indicating a potential downside of 9.91%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 31.40%. Given DBV Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than Quidel Corporation.

Profitability

This table compares Quidel Corporation and DBV Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quidel Corporation 1.83% 1.94% 1.02%
DBV Technologies N/A N/A N/A

Earnings and Valuation

This table compares Quidel Corporation and DBV Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Quidel Corporation $214.97 million 4.23 $39.80 million $0.10 273.83
DBV Technologies $8.44 million 201.17 -$128.50 million N/A N/A

Quidel Corporation has higher revenue and earnings than DBV Technologies.

Volatility & Risk

Quidel Corporation has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Insider and Institutional Ownership

89.2% of Quidel Corporation shares are owned by institutional investors. Comparatively, 48.2% of DBV Technologies shares are owned by institutional investors. 22.0% of Quidel Corporation shares are owned by insiders. Comparatively, 15.3% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Quidel Corporation beats DBV Technologies on 7 of the 12 factors compared between the two stocks.

About Quidel Corporation

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company’s product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.